April 25, 2017
Results of a PI/II clinical study of Eisai’s anti-fractalkine monoclonal antibody (development code: E6011) in Japanese patients with rheumatoid arthritis (RA) have suggested its clinical efficacy and novel pharmacotherapies that target fractalkine could provide new treatment options for RA. The...read more